NetScientific PLC PDS Phase 2 Clinical Trial Update (7206U)
06 Dezembro 2021 - 11:52AM
UK Regulatory
TIDMNSCI
RNS Number : 7206U
NetScientific PLC
06 December 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Phase 2 Clinical Trial Update
PDS Biotech Provides Recruitment update for National Cancer
Institute-Led Phase 2 Clinical Trial of PDS0101-Based
Combination
London, UK - 06 December 2021 - NetScientific plc (AIM: NSCI),
the international life sciences and sustainability technology
investment and commercialisation Group, announces that its
portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB),
has announced the reopening of recruitment in the National Cancer
Institute (NCI)-led Phase 2 clinical trial (NCT04287868) evaluating
PDS0101 (Versamune(R)-HPV16) in combination with two
investigational immune-modulating agents in advanced HPV
cancers.
The suspension of recruitment was administrative in nature and
was unrelated to any specific safety or efficacy concerns
associated with the triple combination being studied. As a result,
during the recruitment suspension, patients already enrolled in the
study continued to receive scheduled treatment. The timing of
clinical results from this trial is not expected to be affected by
the pause in recruitment of new patients.
The trial is evaluating the novel triple combination in two
groups of patients. Firstly, in second line treatment of recurrent
or metastatic HPV-positive cancers including anal, cervical, head
and neck, penile, vaginal, and vulvar cancers in patients who are
naïve to checkpoint inhibitors and have not responded to at least
one standard of care therapy. Secondly in third line treatment of
the above recurrent or metastatic HPV-positive cancers in patients
who have not responded to at least two standard of care therapies
including checkpoint inhibitor treatment.
Dr. Lauren V. Wood, PDS Biotech's Chief Medical Officer
commented: "We are pleased that the NCI, part of the National
Institutes of Health, quickly obtained IRB approval to resume
recruitment in this important trial. We believe the interim data
demonstrated that this combination has the potential to
significantly improve clinical outcomes for patients with advanced,
refractory HPV16-positive cancers who have limited treatment
options. Our approach of treating multiple types of cancer based on
their molecular profiles rather than tissue location, may have the
potential to provide safe Versamune(R)-based treatment options to
an expanded population of patients suffering from multiple types of
cancer and at different stages of disease."
Ilian Iliev, CEO of NetScientific, commented: "As anticipated in
our announcement dated 21 October 2021, this temporary suspension
in the recruitment for patients for one of the PDS Biotech Phase 2
clinical trials has now been restarted. The suspension was
administrative in nature, unrelated to any specific safety or
efficacy concerns, and has not affected the timing of expected
clinical results from this trial. Alongside this NCI trial, PDS is
continuing to make progress in the other Phase 2 trials and other
projects underway. We look forward to clinical data and the next
milestones, and remain supportive of PDS' management."
Full details of the announcement from PDS can be viewed here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/576-iotechrovidesecruitmentupdateforationalancer20211206
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR
Nick Rome/ Paul McManus/ 07748 325 236, 07980 541 893
Nicholas Johnson or 07884 664 686
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK and USA,
as well as globally.
With the acquisition of EMV Capital in August 2020, the Group
doubled its portfolio from 8 to 17 companies, either through direct
subsidiary, balance sheet investment or capital under advisory,
varying from start-up private companies to publicly listed
equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: www.netscientific.net ).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDTFBITMTIMBPB
(END) Dow Jones Newswires
December 06, 2021 09:52 ET (14:52 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024